Monomeric CRP is Elevated in Patients with COPD Compared to Non-COPD Control Persons

被引：10

作者：

Munuswamy, Revathy ^{[1
]}

De Brandt, Jana ^{[2
]}

Burtin, Chris ^{[2
]}

Derave, Wim ^{[3
]}

Aumann, Joseph ^{[4
]}

Spruit, Martijn A. ^{[5
,6
]}

Michiels, Luc ^{[1
]}

机构：

[1] Hasselt Univ, Biomed Res Inst BIOMED, Fac Med & Life Sci, Hasselt, Belgium

[2] Hasselt Univ, Biomed Res Inst BIOMED, Fac Rehabil Sci, Rehabil Res Ctr REVAL, Hasselt, Belgium

[3] Univ Ghent, Dept Movement & Sports Sci, Ghent, Belgium

[4] Jessa Hosp, Dept Pneumol, Hasselt, Belgium

[5] CIRO, Dept Res & Dev, Horn, Netherlands

[6] Maastricht Univ, Med Ctr, NUTRIM Sch Nutr & Translat Res Metab, Fac Hlth Med & Life Sci,Dept Resp Med, Maastricht, Netherlands

来源：

JOURNAL OF INFLAMMATION RESEARCH | 2021年 / 14卷

关键词：

COPD; low-grade systemic inflammation; pCRP; mCRP;

D O I：

10.2147/JIR.S320659

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chronic low-grade systemic inflammation is frequently observed in patients with chronic obstructive pulmonary disease (COPD), e.g., elevated pentameric CRP (pCRP). However, pCRP can dissociate to form monomeric CRP (mCRP) which exhibits a clear pro inflammatory behaviour in contrast to the more anti-inflammatory properties of pCRP. Therefore, mCRP may be an informative biomarker to demonstrate chronic low-grade systemic inflammation. This was confirmed by analysing serum samples from 38 patients with COPD and 18 non-COPD control persons (NCCP). mCRP was significantly elevated in patients with COPD vs. NCCP, indicating that mCRP might be considered as a new sensitive marker of chronic low-grade systemic inflammation.

引用

页码：4503 / 4507

页数：5

共 7 条

[1] Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
Agusti, Alvar
Edwards, Lisa D.
Rennard, Stephen I.
MacNee, William
Tal-Singer, Ruth
Miller, Bruce E.
Vestbo, Jorgen
Lomas, David A.
Calverley, Peter M. A.
Wouters, Emiel
Crim, Courtney
Yates, Julie C.
Silverman, Edwin K.
Coxson, Harvey O.
Bakke, Per
Mayer, Ruth J.
Celli, Bartolome
[J]. PLOS ONE, 2012, 7 (05):
[2] C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure
Aksu, Funda
Capan, Nermin
Aksu, Kurtulus
Ofluoglu, Ruhsar
Canbakan, Sema
Yavuz, Bunyamin
Akin, Kadir Okhan
[J]. JOURNAL OF THORACIC DISEASE, 2013, 5 (04) : 414 - 421
[3] Monomerization of C-reactive protein requires glycoprotein IIb-IIIa activation: pentraxins and platelet deposition
De La Torre, R.
Pena, E.
Vilahur, G.
Slevin, M.
Badimon, L.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (11) : 2048 - 2058
[4] Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease
Hurst, John R.
Donaldson, Gavin C.
Perera, Wayomi R.
Wilkinson, Tom M. A.
Bilello, John A.
Hagan, Gerry W.
Vessey, Rupert S.
Wedzicha, Jadwiga A.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (08) : 867 - 874
[5] C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis
Leuzzi, Giovanni
Galeone, Carlotta
Taverna, Francesca
Suatoni, Paola
Morelli, Daniele
Pastorino, Ugo
[J]. EUROPEAN RESPIRATORY REVIEW, 2017, 26 (143)
[6] Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD
Perng, D-W.
Tao, C-W.
Su, K-C.
Tsai, C-C.
Liu, L-Y.
Lee, Y-C.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (04) : 778 - 784
[7] Trial JoAnn, 2016, Inflamm Cell Signal, V3

← 1 →